FDA vs EMA: The Camizestrant Controversy

Key Takeaways

• On May 27, 2026, AstraZeneca said FDA extended the camizestrant PDUFA date to review additional SERENA-6 analyses, including ctDNA clearance data linked to longer-term outcomes.
• On May 22, 2026, CHMP recommended EU approval of camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection in first-line therapy without disease progression.
• SERENA-6 showed a 56% reduction in risk of progression or death (HR 0.44; median PFS 16.0 vs 9.2 months) for the camizestrant switch strategy.
• Camizestrant is already approved in the UAE and Saudi Arabia in this setting; U.S., Japan, and other filings remain under review.

What actually happened with Camizestrant at FDA and EMA?

AstraZeneca’s May 27, 2026 RNS states the FDA will extend the Prescription Drug User Fee Act date to review additional data supporting the NDA for camizestrant plus CDK4/6 inhibition in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.

That follows an April 2026 Oncologic Drugs Advisory Committee session that did not reach a majority vote in favor of the benefit of switching to camizestrant after ctDNA-detected ESR1 mutation before radiographic progression.

Five days earlier, CHMP adopted a positive opinion recommending EU approval in the same SERENA-6-defined setting. A CHMP opinion is not yet a European Commission marketing authorization, but it is the key scientific gate.

What evidence underpins the Camizestrant filings?

Both regulators are reviewing SERENA-6, a Phase III ctDNA-guided switch trial. Results were presented at ASCO 2025 and published in The New England Journal of Medicine (Bidard et al.).

At interim analysis, camizestrant plus continued CDK4/6 inhibitor cut progression-or-death risk by 56% versus staying on an aromatase inhibitor plus CDK4/6 inhibitor (HR 0.44; 95% CI 0.31–0.60; p<0.00001). Median PFS was 16.0 versus 9.2 months.

AstraZeneca later reported a statistically significant PFS2 benefit (25.7 vs 19.1 months; HR 0.63) while overall survival remained immature (HR 0.87; 95% CI 0.57–1.30). FDA Breakthrough Therapy Designation for the combination was granted in May 2025.

Why do U.S. and EU reviewers appear to diverge?

ODAC’s concern centered on whether early endocrine switching based on ctDNA ESR1 detection—before conventional progression—delivers patient-relevant benefit when overall survival is still maturing. CHMP judged the same PFS and emerging PFS2 package sufficient to recommend approval.

For oncology strategy teams, the split highlights how surrogate endpoints and novel monitoring designs can clear one major region while another demands more longitudinal evidence. AstraZeneca said additional ctDNA clearance analyses tied to longer-term efficacy would be presented June 2, 2026 at ASCO.

What should pharma teams and investors monitor next?

Key watch items are any new FDA action date, the content of the ASCO 2026 ctDNA analyses, European Commission decision timing after CHMP, and labeling language around ctDNA testing requirements.

Competitive context includes other oral selective estrogen receptor degraders already marketed in later-line settings. Camizestrant’s first-line switch claim is strategically distinct if regulators accept the SERENA-6 paradigm.

See also NovaPharma coverage of camizestrant, oncology disease intelligence, and the prior FDA delay analysis.

Frequently Asked Questions

Primary Sources

• AstraZeneca RNS — FDA PDUFA extension for camizestrant
• AstraZeneca — CHMP positive opinion for camizestrant
• NEJM — First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer